» Articles » PMID: 35920560

Proteomic Profiling of Hypoplastic Lungs Suggests an Underlying Inflammatory Response in the Pathogenesis of Abnormal Lung Development in Congenital Diaphragmatic Hernia

Abstract

The pathogenesis of lung hypoplasia in congenital diaphragmatic hernia (CDH), a common birth defect, is poorly understood. The diaphragmatic defect can be repaired surgically, but the abnormal lung development contributes to a high mortality in these patients. To understand the underlying pathobiology, we compared the proteomic profiles of fetal rat lungs at the alveolar stage (E21) that were either exposed to nitrofen in utero (CDH lungs, n=5) or exposed to vehicle only (non-CDH control lungs, n=5). Pathway analysis of proteomic datasets showed significant enrichment in inflammatory response proteins associated with cytokine signaling and Epstein Barr Virus in nitrofen CDH lungs. Among the 218 significantly altered proteins between CDH and non-CDH control lungs were Tenascin C, CREBBP, LYN, and STAT3. We showed that Tenascin C was decreased around the distal airway branches in nitrofen rat lungs and human CDH lungs, obtained from stillborn fetuses that did not receive pre- or postnatal treatment. In contrast, STAT3 was significantly increased in the airway epithelium of nitrofen lungs at E21. STAT3 inhibition after direct nitrofen exposure to fetal rat lung explants (E14.5) partially rescued the hypoplastic lung phenotype ex vivo by increasing peripheral lung budding. Moreover, we demonstrated that several STAT3-associated cytokines (IL-15, IL-9, andIL-2) are increased in fetal tracheal aspirates of CDH survivors compared with nonsurvivors after fetoscopic endoluminal tracheal occlusion. With our unbiased proteomics approach, we showed for the first time that downstream inflammatory processes are likely involved in the pathogenesis of abnormal lung development in CDH.

Citing Articles

Fetoscopic Endoluminal Tracheal Occlusion-Synergic Therapies in the Prenatal Treatment of Congenital Diaphragmatic Hernia.

Bara Z, Gozar H, Nagy N, Gurzu S, Derzsi Z, Forro T Int J Mol Sci. 2025; 26(4).

PMID: 40004103 PMC: 11855672. DOI: 10.3390/ijms26041639.


Amniotic fluid stem cell extracellular vesicles as a novel fetal therapy for pulmonary hypoplasia: a review on mechanisms and translational potential.

Doktor F, Antounians L, Figueira R, Khalaj K, Duci M, Zani A Stem Cells Transl Med. 2025; 14(1.

PMID: 39823257 PMC: 11740888. DOI: 10.1093/stcltm/szae095.


Validation and in silico function prediction of circtial1 as a novel marker of abnormal lung development in nitrofen-induced congenital diaphragmatic hernia (CDH).

Jank M, Kraljevic M, Ozturk Aptekmann A, Patel D, Boettcher M, Leduc R Pediatr Surg Int. 2024; 41(1):40.

PMID: 39708130 DOI: 10.1007/s00383-024-05911-w.


Sex-specific differences in the severity of pulmonary hypoplasia in experimental congenital diaphragmatic hernia and implications for extracellular vesicle-based therapy.

Doktor F, Lo E, Fortuna V, Khalaj K, Garcia M, Figueira R Pediatr Surg Int. 2024; 40(1):278.

PMID: 39467854 DOI: 10.1007/s00383-024-05856-0.


Fetal hypoplastic lungs have multilineage inflammation that is reversed by amniotic fluid stem cell extracellular vesicle treatment.

Antounians L, Figueira R, Kukreja B, Litvack M, Zani-Ruttenstock E, Khalaj K Sci Adv. 2024; 10(30):eadn5405.

PMID: 39058789 PMC: 11277482. DOI: 10.1126/sciadv.adn5405.